Startsida
Hjälp
Sök i LIBRIS databas

     

 

Sökning: onr:6ksb80m84s0jz38z > C-reactive protein-...

C-reactive protein- and clinical symptoms-guided strategy in term neonates with early-onset sepsis reduced antibiotic use and hospital stay: a quality improvement initiative [Elektronisk resurs]

Gyllensvärd, Johan (författare)
Ingemansson, Fredrik (författare)
Hentz, Elisabet (författare)
Studahl, Marie (författare)
Elfvin, Anders (författare)
H.K.H. Kronprinsessan Victorias barn- och ungdomssjukhus (utgivare)
Linköpings universitet Institutionen för biomedicinska och kliniska vetenskaper (utgivare)
Linköpings universitet Medicinska fakulteten (utgivare)
Publicerad: BMC, 2020
Engelska.
Ingår i: BMC Pediatrics. - 1471-2431. ; 20:1
Läs hela texten
Läs hela texten
Läs hela texten
  • E-artikel/E-kapitel
Sammanfattning Ämnesord
Stäng  
  • Background: Early-onset sepsis (EOS) is a potentially life-threatening complication of birth. Clinical symptoms are often unspecific and biomarkers have low predictive values for EOS. Therefore, clinical suspicion often leads to antibiotic therapy in neonates with a negative blood culture. In the study we evaluated if a quality improvement initiative could reduce unwarranted antibiotic use in a safe way in term neonates with culture-negative sepsis. Methods: The quality improvement initiative included new treatment guidelines and were introduced on 11 June 2018. The guidelines included C-reactive protein- and clinical symptoms-guided decision-making and shorter intravenous antibiotic therapy. All term neonates treated for EOS at Ryhov Hospital, Jonkoping, Sweden were studied before (period 1: 2016-2017) and after the introduction of the new guidelines (period 2: 11 June 2018 to 30 Sept 2019). Laboratory and clinical data were analysed. Results: There were 7618 term neonates in period 1 and 5005 term neonates in period 2. We identified 140 (1.8%) EOS in period 1 and 97 (1.9%) EOS in period 2. During period 1 and 2, there were 61 (61/140, 44%) and 59 (59/97, 61%) EOS neonates, respectively, who met the criteria for shorter antibiotic treatment. The number of positive blood cultures were seven (0.92/1000 live births) and five (1.0/1000 live births) in period 1 and 2. The median C-reactive protein were 52 mg/L (37-62) in period 1 and 42 mg/L (31-56) in period 2 in the group who met the criteria of the guidelines. The duration of antibiotic therapy (Median: seven vs. five days, p < 0.001) and hospital stay (Median: seven vs. five days, p < 0.001) as well as healthcare costs (decreased by euro122,000/year) was reduced in the group who met the criteria after the introduction of the guidelines. Conclusion: C-reactive protein- and clinical symptoms-guided decision-making for EOS significantly decreased the duration of antibiotic therapy and hospital stay, and hence reduced healthcare costs, with no reinfection in a cohort of term infants. 

Ämnesord

Medical and Health Sciences  (hsv)
Clinical Medicine  (hsv)
Pediatrics  (hsv)
Medicin och hälsovetenskap  (hsv)
Klinisk medicin  (hsv)
Pediatrik  (hsv)

Genre

government publication  (marcgt)

Indexterm och SAB-rubrik

Bacterial infection; C-reactive protein; Neonatal sepsis; Antibiotic therapy; Antibiotic stewardship; Quality improvement
Inställningar Hjälp

Ingår i annan publikation. Gå till titeln BMC Pediatrics

Om LIBRIS
Sekretess
Hjälp
Fel i posten?
Kontakt
Teknik och format
Sök utifrån
Sökrutor
Plug-ins
Bookmarklet
Anpassa
Textstorlek
Kontrast
Vyer
LIBRIS söktjänster
SwePub
Uppsök

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy